Business Development Partnerships - Scientists in a lab

Partner with us

DMK Pharmaceuticals is looking to explore strategic commercial or development opportunities in several neuro-therapeutic areas such as Opioid Use Disorder (OUD), urological diseases and Parkinson’s. We believe that developing and strengthening the science and accessibility in these areas is essential to providing better treatment for patients. Our ideal partners share our passion and dedication to saving lives.

Please contact us to talk with our Business Development team.

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit

Check this page for the most recent updates regarding the merger process.